Musty Odor Reason behind another Tylenol Recall

Article

McNeil, producer of over-the-counter drugs like Tylenol and Benadryl, has issued yet another recall due to a musty odor associated with packaging.

The most recent in a series of over-the-counter drug recalls is now Tylenol 8-hour caplets 50 count. Numerous complaints about the odor of these particular packages, which are sold in the United States and Puerto Rico, are what led to the recall by McNeil, despite the company saying that “the risk of adverse medical events is remote.”

An estimated 128,000 bottles will be recalled, the lot of which was made in March at a factory in Fort Washington, Pennsylvania. The most recent recall for McNeil adds to a laundry list of recalls that have added up to tens of millions of bottles, all within the past year. Because of the numerous recalls, McNeil now faces a US congressional probe of quality control lapses.

Reuters reports that the FDA “cited thick dust, grime and contaminated ingredients at the Fort Washington plant. J&J plans to reopen the plant next year, and is using other McNeil plants to help offset lost production of the recalled products.”

Although a recall is obviously never a good thing for a company, this is an especially bad time for McNeil, as the company is scheduled to report third quarter earnings today.

Around the Web

Musty odor sparks another Tylenol recall [Reuters]

More Trouble With Tylenol [NY Times]

That Familiar Musty Odor Hits J&J Again [WSJ]

Related Videos
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Video 6 - "The Role of Eosinophils in Diagnosing COPD"
Video 5 - "Unmet Needs in the COPD Treatment Landscape"
Video 6 - "Treatment Resistance in HIV"
Video 5 - "Importance of Starting HIV Treatment Early"
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Dimitra Skondra, MD, PhD: Protective Effect of Metformin in Geographic Atrophy| Image Credit: University of Chicago
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
Video 3 - "Aligning With 2023 ESC Guidelines in oHCM Treatment"
Robert Rosenson, MD | Credit: Cura Foundation
© 2024 MJH Life Sciences

All rights reserved.